Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?

Job Harenberg; Rupert Bauersachs; Walter Ageno

doi:10.1055/s-0040-1715091

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2021; 47(04): 338-340
DOI: 10.1055/s-0040-1715091

Commentary

Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?

Authors

Job Harenberg

¹Ruprecht Karls University, Heidelberg, Germany

²Doasense GmbH, Heidelberg, Germany
Rupert Bauersachs

³Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany
Walter Ageno

⁴Department of Medicine and Surgery, University of Insubria, Varese, Italy

Abstract

Full Text

References

References
1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22 (08) 983-988
2 Lip GYH, Collet JP, de Caterina R. et al. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Thromb Haemost 2017; 117 (12) 2215-2236
3 Rosendaal FR, VAN Hylckama Vlieg A, Doggen CJ. Venous thrombosis in the elderly. J Thromb Haemost 2007; 5 (Suppl. 01) 310-317
4 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
5 Liang W, Liang H, Ou L. et al; China Medical Treatment Expert Group for COVID-19. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020; (e-pub ahead of print)
6 Alger HM, Williams IV JH, Walchok JG, Bolles M, Fonarow GC, Rutan C. Role of data registries in the time of COVID-19. Circ Cardiovasc Qual Outcomes 2020; 13 (05) e006766
7 Favaloro EJ, McVicker W, Lay M. et al. Harmonizing the International Normalized Ratio (INR): Standardization of methods and use of novel strategies to reduce interlaboratory variation and bias. Am J Clin Pathol 2016; 145 (02) 191-202
8 Refaai MA, Shah V, Fernando R. Performance of the microINR Point-of-Care system: a multicenter clinical trial. Thromb Haemost 2020; 120 (04) 687-691
9 Henry BM, de Oliveira MHS, Benoit S. et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020; 58 (07) 1021-1028
10 Harenberg J, Beyer-Westendorf J, Crowther M. et al; Working Group Members. Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine-a multicenter trial. Thromb Haemost 2020; 120 (01) 132-140
11 Lip GYH, Banerjee A, Boriani G. et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 2018; 154 (05) 1121-1201